ClinicalTrials.Veeva

Menu

Meru Health Program for Cancer Patients With Depression and Anxiety

M

Meru Health

Status

Completed

Conditions

Depression
Anxiety

Treatments

Behavioral: Meru Health Program

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT05588622
22-MERU-117

Details and patient eligibility

About

The primary objective of this study is to evaluate clinical outcomes among people with cancer who participate in a 12-week therapist-supported digital mental health intervention (DMHI) called the Meru Health Program (MHP). Study participants (N=20) will be referred to the MHP through the Cancer Support Community (CSC) Helpline and network of Gilda's Club locations. The main outcomes will be depression symptoms, anxiety symptoms, health-related quality of life (HRQoL), intervention adherence, and intervention satisfaction. The secondary objective will be to determine the acceptability of the screening and referral process from the CSC networks into the MHP. Data pertaining to implementability will be collected from study participants, MHP clinicians, and CSC staff.

Full description

The goal of this single-arm intervention study is to test the feasibility of the Meru Health Program (MHP) in reducing symptoms of depression and anxiety among 20 people with cancer referred from the Cancer Support Community (CSC). The MHP is a 12-week digital mental health intervention delivered via a smartphone app. The intervention focuses on cognitive behavioral techniques and mindfulness skills with the aim of improving mental health symptoms. The platform provides informational videos, skills practices, group discussion, and messaging with a licensed clinician employed by Meru Health. The licensed clinician supports patients as needed and reviews engagement logs within the app. As part of the intervention, depression and anxiety symptoms are measured on a biweekly basis over 12 weeks. For this study, self-reported surveys will be administered at baseline, week 12, and 2-months post-treatment to measure health-related quality of life and intervention satisfaction. In-depth interviews will be conducted with patients. Two focus groups will be conducted with MHP clinicians and CSC navigators to understand barriers and facilitators to the screening processes and intervention delivery.

Enrollment

22 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Positive screen (score >= 3 out of 8) on the anxiety or depression subscale of the CSS 15+ Questionnaire
  • PHQ-9 and/or GAD-7 score >= 5 at clinical intake
  • Willing to commit to the Meru Health Program if selected
  • Proficient in the English language
  • At least 18 years of age at the time of enrollment
  • Has a valid mailing address
  • Owns 1 of the 3 past versions of an Apple or Android mobile phone operating system
  • Currently in active cancer treatment at the time of enrollment

Exclusion criteria

  • Active suicide intent with plan to act
  • Substance use disorder in the past 3 months
  • Lifetime bipolar disorder
  • Lifetime psychotic disorder
  • Currently pregnant
  • Less than 3 months postpartum

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

22 participants in 1 patient group

Treatment Group
Experimental group
Description:
This single-arm study will enroll all 20 participants in the Meru Health Program.
Treatment:
Behavioral: Meru Health Program

Trial contacts and locations

1

Loading...

Central trial contact

Nicholas C Peiper, PhD, MPH; Edward H Brown, MS, MBA

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems